Hepion Pharmaceuticals (NASDAQ:HEPA) Trading 8.8% Higher
Hepion Pharmaceuticals (NASDAQ:HEPA) Trading 8.8% Higher
Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA – Get Rating)'s share price traded up 8.8% during trading on Thursday . The company traded as high as $0.75 and last traded at $0.74. 312,151 shares were traded during trading, a decline of 58% from the average session volume of 736,713 shares. The stock had previously closed at $0.68.
賀邦製藥公司（NASDAQ：HEPA-獲取評級）的股價在周四交易期間上漲了 8.8％。該公司的交易價格高達 0.75 美元，最後交易價為 0.74 美元。在交易過程中成交 312,151 股，較平均交易時段成交量 736,713 股下跌 58%。該股票之前已收盤 0.68 美元。
Analysts Set New Price Targets
分析師設定新的價格目標
A number of equities analysts have recently commented on the company. Brookline Capital Management reissued a "buy" rating on shares of Hepion Pharmaceuticals in a report on Tuesday, January 31st. Alliance Global Partners assumed coverage on Hepion Pharmaceuticals in a report on Monday, January 23rd. They set a "buy" rating for the company.
一些股票分析師最近對該公司發表了評論。布魯克林資本管理公司在 1 月 31 日（星期二）的一份報告中重新發布了對赫平醫藥股份的「買入」評級。聯盟全球合作夥伴承擔了 Hepion 製藥在 1 月 23 日星期一的報告中承擔了報導。他們為公司設定了「購買」評級。
Hepion Pharmaceuticals Stock Performance
赫比安製藥股票表現
The company has a market cap of $59.19 million, a price-to-earnings ratio of -1.32 and a beta of 1.64. The business has a fifty day moving average price of $0.77 and a 200 day moving average price of $0.57.
該公司的市值為 5,919 萬美元，股價與收益比率為 -1.32，測試版為 1.64。該業務的五十天移動平均價為 0.77 美元，200 日移動平均價格為 0.57 美元。
Institutional Investors Weigh In On Hepion Pharmaceuticals
機構投資者權衡 Hepion 製藥
A number of hedge funds and other institutional investors have recently bought and sold shares of HEPA. Renaissance Technologies LLC grew its position in Hepion Pharmaceuticals by 151.7% during the 1st quarter. Renaissance Technologies LLC now owns 126,600 shares of the company's stock worth $163,000 after acquiring an additional 76,300 shares during the last quarter. State Street Corp grew its position in Hepion Pharmaceuticals by 8.1% during the 1st quarter. State Street Corp now owns 348,910 shares of the company's stock worth $450,000 after acquiring an additional 26,194 shares during the last quarter. PVG Asset Management Corp bought a new stake in Hepion Pharmaceuticals during the 3rd quarter worth $55,000. Virtu Financial LLC grew its position in Hepion Pharmaceuticals by 195.6% during the 3rd quarter. Virtu Financial LLC now owns 67,802 shares of the company's stock worth $34,000 after acquiring an additional 44,867 shares during the last quarter. Finally, Envestnet Asset Management Inc. grew its position in Hepion Pharmaceuticals by 45.8% during the 3rd quarter. Envestnet Asset Management Inc. now owns 87,541 shares of the company's stock worth $44,000 after acquiring an additional 27,487 shares during the last quarter. Institutional investors own 9.37% of the company's stock.
一些對沖基金和其他機構投資者最近買賣了 HEPA 的股票。文藝復興技術有限責任公司通過 151.7% 在第一季度增長了在赫邦製藥的地位.文藝復興科技有限責任公司現在擁有該公司股票的 126,600 股，價值 163,000 美元在上一季度獲得額外的 76,300 股後。國街公司在 Hepion 製藥的地位增長 8.1% 在第一季度.州街公司現在擁有該公司股票的 348,910 股，價值 450,000 美元在上一季度額外購買了 26,194 股股票。PVG 資產管理公司在第三季度購買了 Hepion 製藥的新股份，價值 55,000 美元。Virtu 金融有限責任公司通過增長在赫邦製藥的地位 195.6% 在第三季度.維圖金融有限責任公司現在擁有該公司股票的 67,802 股，價值 34,000 美元，在上一季度額外收購了 44,867 股。最後, 安維斯特資產管理公司. 在第三季度增長了 45.8% 在赫邦製藥的地位.安衛斯特資產管理股份有限公司現在擁有該公司股票的 87,541 股，價值 44,000 美元，在上一季度額外收購了 27,487 股股票。機構投資者擁有公司股票的 9.37%。
About Hepion Pharmaceuticals
關於賀邦製藥
(Get Rating)
(取得評分)
Hepion Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the development of drug therapy for treatment of chronic liver diseases. It focuses on the development of its product candidate CRV431, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease.
Hepion 製藥公司是一家生物製藥公司，致力於開發用於治療慢性肝病的藥物治療。它專注於其候選產品 CRV431 的開發，這是一種針對參與肝病進展的生化途徑的環黴素抑製劑。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on Hepion Pharmaceuticals (HEPA)
- MarketBeat Week in Review – 3/27 – 3/31
- What is a Gold IRA, and is it a Viable Investment?
- Is Braze Inc Ready To Rocket Higher?
- Mullen Automotive Makes Deliveries; Short-Squeeze Possible
- Can Frontline Maintain This Momentum?
- 獲取有關赫比安製藥（HEPA）的研究報告的免費副本
- 市場節拍週的回顧 — 3 月 27 日 — 3/31
- 什麼是黃金 IRA 退休賬戶，它是一項可行的投資嗎？
- 是 Braze 公司準備火箭更高嗎？
- 穆倫汽車製造交貨；短擠壓成為可能
- 前線可以保持這種勢頭嗎？
Receive News & Ratings for Hepion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hepion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Hepion 藥品日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Hepion 製藥及相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。